The effect of chromium picolinate and biotin supplementation on glycemic control in poorly controlled patients with type 2 diabetes mellitus: A placebo-controlled, double-blinded, randomized trial
The effect of chromium picolinate and biotin supplementation on glycemic control in poorly controlled patients with type 2 diabetes mellitus: A placebo-controlled, double-blinded, randomized trial
复制标题
DOI：
10.1089/dia.2006.8.636
复制
发表时间：
2006-12-01
影响因子：
5.4
通讯作者：
Geohas, Jeff
中科院分区：
文献类型：
--
作者：
Singer, Gregory M.;Geohas, Jeff
背景资料：临床前研究表明，吡啶甲酸铬和生物素的组合显著增强骨骼肌细胞中的葡萄糖摄取并增强葡萄糖处置。本初步研究旨在确定补充吡啶甲酸铬和生物素是否能改善2型糖尿病患者的血糖控制，尽管使用口服降糖药，血糖控制仍不佳。（2-h葡萄糖> 200 mg/dL;糖化血红蛋白>= 7%），尽管使用口服降糖药治疗，随机接受600 μ g铬作为吡啶甲酸铬和生物素（2mg/天）（Diachrome，Nutrition 21，Inc.，购买，纽约州）除了他们的研究前口服降糖药治疗。结果：治疗4周后，治疗组2 h口服葡萄糖耐量试验中血糖曲线下面积的平均变化为-9.7%，明显大于安慰剂组（平均变化为+5.1%，P <0.03）。治疗组中果糖胺（P <0.03）、甘油三酯（P <0.02）和甘油三酯/高密度脂蛋白胆固醇比值（P <0.05）的降低幅度也更大。没有显着的不良事件归因于吡啶甲酸铬和生物素supplementation.Conclusions：这项试点研究表明，补充吡啶甲酸铬和生物素的组合控制不佳的糖尿病患者接受抗糖尿病治疗改善血糖管理和几个血脂测量。吡啶甲酸铬/生物素补充剂可能是一种有效的预防性营养疗法，对糖尿病控制不佳的人具有改善脂质代谢的潜力。
Background: Preclinical studies have shown that the combination of chromium picolinate and biotin significantly enhances glucose uptake in skeletal muscle cells and enhances glucose disposal. The present pilot study was conducted to determine if supplementation with chromium picolinate and biotin can improve glycemic control in patients with type 2 diabetes mellitus with suboptimal glycemic control despite use of oral antihyperglycemic agents.Methods: Forty-three subjects with impaired glycemic control (2-h glucose >200 mg/dL; glycated hemoglobin >= 7%), despite treatments with oral antihyperglycemic agents, were randomized to receive 600 mu g of chromium as chromium picolinate and biotin (2 mg/day) (Diachrome(R), Nutrition 21, Inc., Purchase, NY) in addition to their prestudy oral antihyperglycemic agent therapy. Measurements of glycemic control and blood lipids were taken at baseline and after 4 weeks.Results: After 4 weeks, there was a significantly greater reduction in the total area under the curve for glucose during the 2-h oral glucose tolerance test for the treatment group (mean change -9.7%) compared with the placebo group (mean change +5.1%, P < 0.03). Significantly greater reductions were also seen in fructosamine (P < 0.03), triglycerides (P < 0.02), and triglycerides/high-density lipoprotein cholesterol ratio (P < 0.05) in the treatment group. No significant adverse events were attributed to chromium picolinate and biotin supplementation.Conclusions: This pilot study demonstrates that supplementation with a combination of chromium picolinate and biotin in poorly controlled patients with diabetes receiving antidiabetic therapy improved glucose management and several lipid measurements. Chromium picolinate/biotin supplementation may represent an effective adjunctive nutritional therapy to people with poorly controlled diabetes with the potential for improving lipid metabolism.